

9TH ANNUAL SUMMIT ON

GENITOURINARY MALIGNANCIES

NOVEMBER 4-8, 2026

FAIRMONT HAMILTON PRINCESS
BERMUDA




TABLE OF CONTENTS

02 SPEAKERS

06 BIOGRAPHIES

SPEAKERS

Emmanuel S. Antonarakis, MD

Clark Endowed Professor of Medicine
Director of GU Oncology, Associate Director of Translation
Division of Hematology, Oncology and Transplantation
University of Minnesota, Masonic Cancer Center
Minneapolis, MN

Leonard Appleman, MD, PhD

Associate Professor of Medicine
Malignant Hematology/Oncology Division
Department of Medicine
UPMC Hillman Cancer Center
Pittsburgh, PA

Saad Atiq, MD

Assistant Professor of Medicine
Genitourinary Medical Oncologist
Icahn School of Medicine at Mount Sinai
New York, NY

Mark W. Ball, MD FACS
Associate Research Physician (Associate Professor)
NCI Liaison to Surgical Administrative Committee/SAC Co-Chair
Associate Program Director, Urologic Oncology Fellowship
Urologic Oncology Branch
National Cancer Institute, NIH
Bethesda, MD

Erin Bange, MD, MSCE

Assistant Attending Physician
Genitourinary Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Katy Beckermann, MD, PhD

Medical Director GU Clinical Research
Tennessee Oncology
Jessica Jones, Research Administrative Assistant
Nashville, TN

Trinity J. Bivalacqua, MD, PhD

Director, Urologic Oncology
Co-Director, Genitourinary Cancer Service Line,
Abramson Cancer Center
Professor of Surgery
Hospital of the University of Pennsylvania
Philadelphia, PA

Jacqueline T. Brown, MD

Assistant Professor
Associate Medical Director, Ambulatory Infusion Center
Winship Cancer Institute of Emory University
Department of Hematology and Medical Oncology
Atlanta, GA

James Brugarolas, MD, PhD

Director, Kidney Cancer Program
Sherry Wigley Crow Endowed Chair in Cancer Research
Professor, Internal Medicine/ Hematology-Oncology
Cancer Biology, Genetics, Development and Disease
Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, TX

Corbin Eule, MD

Assistant Professor
Genitourinary (GU) Medical Oncology
University of Colorado School of Medicine
Aurora, CO

Catherine Fahey, MD, PhD

Assistant Professor of Medicine
Division of Oncology,
University of North Carolina at Chapel Hill
Chapel Hill, NC

Christopher Gaffney, MD

Assistant Attending Surgeon
Urologic Surgeon
Memorial Sloan Kettering Cancer Center
New York, NY

Timothy Gilligan, MD

Vice-Chair for Education
Associate Professor of Medicine
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Hanan Goldberg, MD, MSc

Assistant Professor
Department of Urology
SUNY Upstate Medical University
New Hartford, NY

Amir Goldkorn, MD

Professor of Medicine and Cancer Biology
Balakrishnan Chair for Cancer Research
Chief, Section of Laboratory Cancer Research
Division of Medical Oncology
Associate Director for Translational Research
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Theodore Stewart Gourdin, MD

Associate Professor
Genitourinary Medical Oncology
Hollings Cancer Center/ Medical University of South Carolina
Charleston, SC

SPEAKERS

Brendan J. Guercio, MD

Assistant Professor, Department of Medicine
Director for Genitourinary Medical Oncology
James P. Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, NY

Hans Hammers, MD, PhD

Professor
Eugene P. Frenkel, M.D. Scholar in Clinical Medicine
Department of Internal Medicine
Division of Hematology and Oncology
UT Southwestern Medical Center
Dallas, TX

Michael E. Hurwitz

Associate Professor of Medicine
Yale Cancer Center
Program Director, Hematology/Oncology Fellowship
Yale School of Medicine
New Haven, CT

Rohit Jain, MBBS, MD

Associate Professor of Medicine
Division of Genitourinary Oncology
Weill Cornell Medicine
Attending Physician
New York-Presbyterian Hospital-Weill Cornell Medical Center
New York, NY

Angela Y. Jia, MD, PhD

Assistant Professor, Radiation Oncology
Director, GU Radiation Oncology
Co-Lead, GU Disease Program
Associate Residency Program Director
University Hospitals Cleveland Medical Center
Cleveland, OH

Eric Jonasch, MD

Professor
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Prateek Khanna, MBBS

Medical Oncologist
Dana-Farber Cancer Institute
Instructor in Medicine
Harvard Medical School
Boston, MA

Jennifer King, MD

Assistant Professor of Clinical Medicine
Associate Fellowship Program Director, Division of
Hematology/Oncology
Indiana University Simon Comprehensive Cancer Center
Indianapolis, IN

Janet Kukreja, MD, MPH, FACS

Director of Urologic Oncology
Associate Professor, Surgery-Urology
University of Colorado
Aurora, CO

Andrew T. Lenis, MD

Assistant Professor of Urology
Department of Urology
Columbia University Irving Medical Center
New York, NY

Murilo De Almeida Luz, MD

Assistant Professor of Urology
Icahn School of Medicine at Mount Sinai
New York, NY

Timothy M. Kuzel, MD, FACP

Clinical Professor of Medicine, Feinberg School of Medicine,
Northwestern University
Associate Director of Clinical Research Network, Robert H. Lurie
Comprehensive Cancer Center
Distinguished Physician, St George Foundation
Oncology Service Line Director, NM South Region
Chicago, IL

Hannah Dzimitrowicz McManus, MD

Assistant Professor of Medicine
Division of Medical Oncology
Department of Medicine
Duke University Medical Center

Mamta Parikh, MD, MS

Associate Professor,
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and Urology
Chief, Genitourinary Oncology
Director of Genitourinary Oncology, Co Director Signal
Transduction Program
Yale School of Medicine
New Haven, CT

SPEAKERS

Dana E. Rathkopf, MD

Member, Memorial Hospital
Memorial Sloan Kettering Cancer Center
Clinical Professor of Medicine
Weill Cornell Medical College
New York, NY

Rosa Nadal Rios, MD, PhD

GU Medical Oncology
Associate Professor
University of Washington School of Medicine
Fred Hutchinson Cancer Center.
Seattle, WA

Charles James Ryan, MD

Member
Attending Physician, Memorial Sloan Kettering Cancer Center
New York, NY

Oliver Sartor, MD

Director, Transformational Prostate Cancer Research Center
LCMC Health
Metairie, LA

David B. Solit, MD

Geoffrey Beene Chair in Cancer Research
Director, Marie-Josée and Henry R. Kravis Center for
Molecular Oncology
Chief, Molecular Medicine Service, Human Oncology and
Pathogenesis Program
Memorial Sloan Kettering Cancer Center
New York, NY

Srikala Sridhar, MD, MSc, FRCPC

Staff Medical Oncologist
GU Site Group Lead
Princess Margaret Cancer Center
Professor, Medical Oncology,
University of Toronto,
Toronto, Ontario, Canada

Walter Stadler, MD, FACP, FASCO

Chief Clinical Officer,
City of Hope Cancer Center Chicago
Professor, Department of Medical Oncology &
Therapeutics Research
Chicago, IL

Chad Tang, MD

Associate Professor
Department of Genitourinary Radiation Oncology
Division of Radiation Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Hong Truong, MD, MS

Urologic Surgeon
Memorial Sloan Kettering Cancer Center
New York, NY

Ulka Vaishampayan, MD, FASCO

Beverly Mitchell Research Professor of Oncology
Co-Leader of Translational Clinical Research Program
University of Michigan/Rogel Cancer Center
Ann Arbor MI

Sara E. Wobker, MD, MPH

Associate Professor with Tenure
Department of Pathology and Laboratory Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC



Emmanuel S. Antonarakis, MD

*Clark Endowed Professor of Medicine
Director of GU Oncology, Associate Director of Translation
Division of Hematology, Oncology and Transplantation
University of Minnesota, Masonic Cancer Center
Minneapolis, MN*

Dr Antonarakis is the Clark Endowed Professor of Medicine and Director of Genitourinary Oncology in the Division of Hematology/Oncology and Transplantation at the University of Minnesota. He also serves as the Associate Director for Translational Research at the Masonic Cancer Center. Previously he was Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, the Director of Prostate Cancer Medical Oncology Research, and the Co-Director of the Prostate Cancer Multi-Disciplinary Clinic at Johns Hopkins. Dr Antonarakis is an expert on the clinical management of advanced prostate cancer and other genitourinary malignancies. He has received numerous awards for his translational research and his teaching skills. He is involved in mentoring fellows and junior faculty in the clinical care of genitourinary cancers and the development of translational clinical trials related to prostate cancer.

Dr Antonarakis' research focuses on drug development and clinical trial design for patients with prostate cancer, as well as cancer genetics and genomics. More specifically, he is exploring novel androgen-directed therapies, genetically targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, using germline and cancer genomics to inform precision oncology approaches. He also has an interest in liquid biomarker development, specifically the clinical utility of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is the PI of multiple phase II and III prostate cancer trials and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the ECOG-ACRIN and Alliance Cooperative Groups, as well as the NCI Prostate Cancer Task Force and the NCCN Prostate Cancer Panel. In 2021, he was elected to the American Society for Clinical Investigation (ASCI). He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 410 peer-reviewed scientific articles, several book chapters, and has edited two textbooks on prostate cancer.



Leonard Appleman, MD, PhD

*Associate Professor of Medicine
Malignant Hematology/Oncology Division
Department of Medicine
UPMC Hillman Cancer Center
Pittsburgh, PA*

Leonard Appleman, MD is an Oncology Specialist in Pittsburgh, PA and has over 27 years of experience in the medical field. Dr. Appleman has extensive experience in Renal Neoplasms & Resection. He graduated from New York University School of Medicine medical school in 1995. His current research efforts in the field of tumor immunology include collaboration with Dr. Pawel Kalinski, conducting clinical trial of an autologous dendritic cell vaccine in patients with biochemical recurrence of prostate cancer (UPCI 06-070). Dr. Appleman is also working with Dr. Michael Lotze on another investigator initiated phase I study of high dose interleukin-2 plus hydroxychloroquine (UPCI 11-080) and has co-authored a review on inhibiting autophagy in renal cell carcinoma with his collaborators (Lotze, Maranchie and Appleman 2013, Cancer J.). He is site principal investigator for the NCI-funded Cancer Immunotherapy Trials Network (CITN) study of interleukin-7 and sipuleucel-T for men with castration-refractory prostate cancer and was the site PI for the Cytokine Working Group IL-2 Select study (McDermott et al. 2014, Clin. Cancer Res.). He also serves as site PI for several industry-sponsored studies that are investigating cancer immunotherapy. One of these studies was presented at ASCO in 2014 (Choueiri et al.).




Saad Atiq, MD

*Assistant Professor of Medicine
Genitourinary Medical Oncologist
Icahn School of Medicine at Mount Sinai
New York, NY*

Dr. Saad Atiq is a medical oncologist at the Icahn School of Medicine at Mount Sinai in New York, where he specializes in the care of patients with genitourinary malignancies. He earned his MD from the University of Arkansas for Medical Sciences in 2019, followed by residency training at Duke University Hospital. He subsequently pursued advanced fellowship training in medical oncology, further developing expertise in translational and clinical cancer research.

Dr. Atiq's research interests focus on advancing therapeutic strategies for genitourinary cancers, particularly bladder cancer. His work explores novel combination treatment regimens and mechanisms of resistance to therapy, with the goal of improving patient outcomes through translational research. He has also been recognized for his commitment to mentorship and academic oncology, contributing to initiatives that support the development of future physician-scientists in cancer research.



Mark W. Ball, MD, FACS

Associate Research Physician (Associate Professor)
NCI Liaison to Surgical Administrative Committee/SAC Co-Chair
Associate Program Director, Urologic Oncology Fellowship
Urologic Oncology Branch
National Cancer Institute, NIH
Bethesda, MD

Dr. Mark Ball is an attending surgeon and board-certified urologist specializing in urologic oncology. He received his undergraduate degree in biochemistry and molecular biology from Centre College, graduating magna cum laude and Phi Beta Kappa. He received his M.D. from the Johns Hopkins University School of Medicine. He completed his internship and residency at the James Buchanan Brady Urological Institute at Johns Hopkins. He subsequently completed a Society of Urologic Oncology-accredited fellowship at the National Cancer Institute

Dr. Ball is the highest volume robotic kidney surgeon in the metropolitan Washington D.C. area, based at the National Cancer Institute. He has a particular interest in robotic partial nephrectomy and robotic partial adrenalectomy for hereditary kidney cancer syndromes, having successfully removed over 1,000 kidney tumors.



Erin Bange, MD, MSCE

Assistant Attending Physician
Genitourinary Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Erin Bange, MD, MSCE, is a medical oncologist at Memorial Sloan Kettering Cancer Center (MSKCC) specializing in genitourinary malignancies, including prostate, bladder, kidney, and testicular cancers. She practices at the Sidney Kimmel Center for Prostate and Urologic Cancers in New York. Dr. Bange earned her medical degree from Thomas Jefferson University and completed her residency in internal medicine at the Hospital of the University of Pennsylvania, followed by fellowship training in medical oncology. She also earned a Master of Science in Clinical Epidemiology (MSCE), reflecting her strong foundation in clinical research and outcomes science.

Dr. Bange's research focuses on improving outcomes and quality of life for patients with genitourinary cancers, with particular interest in patient-centered care, treatment-related toxicities, and survivorship. She has contributed to clinical and translational research in bladder and prostate cancer and has received recognition including the Conquer Cancer Young Investigator Award and ASCO Merit Award. Through her work at MSKCC, she is actively involved in advancing innovative therapies and evidence-based approaches in genitourinary oncology while guiding patients and families through complex treatment decisions.



Katy Beckermann, MD, PhD

*Medical Director GU Clinical Research
Tennessee Oncology
Jessica Jones, Research Administrative Assistant
Nashville, TN*

Dr. Katy Beckermann is a board-certified medical oncologist specializing in genitourinary malignancies. She completed her entire advanced medical and scientific training at Vanderbilt University, where she earned her medical degree, a PhD, and subsequently completed her specialized fellowship training. Dr. Beckermann serves as the Medical Director of Genitourinary Clinical Research at Tennessee Oncology in Nashville, Tennessee.

Her clinical expertise and research focus heavily on developing and leading innovative clinical trials for urologic cancers, aiming to bring advanced therapeutic options to patients navigating kidney, bladder, and prostate malignancies. Her work is particularly relevant to the evolving management of advanced kidney cancer, including approaches after immune checkpoint inhibitor therapy.



Trinity J. Bivalacqua, MD, PhD

*Director, Urologic Oncology
Co-Director, Genitourinary Cancer Service Line,
Abramson Cancer Center
Professor of Surgery
Hospital of the University of Pennsylvania
Philadelphia, PA*

Dr. Trinity J. Bivalacqua, MD, PhD, is a nationally recognized urologic oncologist and academic leader at the University of Pennsylvania, where he serves as Professor and Chair of the Department of Urology at the Perelman School of Medicine. He is also Urologist-in-Chief for the University of Pennsylvania Health System. Dr. Bivalacqua earned his MD and PhD degrees from Johns Hopkins University School of Medicine and completed his residency training in urology at Johns Hopkins Hospital, followed by advanced fellowship training in urologic oncology. He has built an international reputation for excellence in the surgical and multidisciplinary management of genitourinary malignancies, particularly bladder cancer.

Dr. Bivalacqua's clinical and translational research focuses on bladder cancer biology, immunotherapy, mechanisms of treatment resistance, and the development of novel therapeutics for invasive bladder cancer. He has led numerous investigator-initiated and cooperative group clinical trials evaluating innovative approaches in urothelial carcinoma and other GU malignancies. Widely published in leading peer-reviewed journals, Dr. Bivalacqua has received multiple honors for his contributions to urologic oncology and continues to advance precision medicine and translational research efforts aimed at improving outcomes for patients with genitourinary cancers.



Jacqueline T. Brown, MD

Assistant Professor

Associate Medical Director, Ambulatory Infusion Center

Winship Cancer Institute of Emory University

Department of Hematology and Medical Oncology

Atlanta, GA

Dr. Jacqueline T. Brown serves as an Assistant Professor and the Associate Medical Director of the Ambulatory Infusion Center at Winship Cancer Institute of Emory University. She completed her medical degree from University of Rochester School of Medicine & Dentistry and Residency in Internal Medicine from University of Virginia and Fellowship in Hematology/Oncology from Emory University School of Medicine.

Dr. Brown's clinical and research interests focus on improving supportive care and optimizing infusion services for patients undergoing complex cancer therapies. She has contributed to advancing infusion center protocols and enhancing patient safety and comfort during treatment. Her leadership at Winship has been instrumental in expanding access to advanced therapies and integrating multidisciplinary care strategies. Dr. Brown is also actively involved in mentoring trainees and contributing to quality improvement initiatives, reflecting her commitment to excellence in oncology care and education.



James Brugarolas, MD, PhD

*Director, Kidney Cancer Program
Sherry Wigley Crow Endowed Chair in Cancer Research
Professor, Internal Medicine/ Hematology-Oncology
Cancer Biology, Genetics, Development and Disease
Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, TX*

Dr. Brugarolas is the founding Director of the Kidney Cancer Program (KCP) at UT Southwestern (UTSW) Medical Center and the Principal Investigator of the Specialized Program of Research Excellence (SPORE), one of two such programs for kidney cancer in the country. Dr. Brugarolas, a practicing oncologist and investigator, is a tenured Professor in Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease, and is the Sherry Wigley Crow Endowed Chair in Cancer Research.

Recognized for its patient care with a UTSW Leaders in Clinical Excellence Program Award, for its innovation with a finalist Healthcare Innovation Award by D CEO & Dallas Innovates, and for its research with a SPORE Award by the National Cancer Institute (NCI), the KCP is a leading program in the country. KCP is driving advances in patient care as exemplified by survival rates that triple national benchmarks, the development of a first-in-class drug going from gene discovery to FDA approval, and of novel radiation applications. A KCP engine, the Brugarolas laboratory, spans the spectrum from fundamental to clinical research. Supporting precision medicine, discoveries by the lab led to the identification of kidney cancer causing genes, established the foundation for a molecularly-based classification, developed the first mouse models reproducing the human disease, established HIF-2 as the first core dependency, identified drivers of tumor grade, and reported the first empiric characterization of the tumor microenvironment identifying a pan-inflammatory subtype providing a biological explanation for elusive prognostic factors.

A member of the American Society for Clinical Investigation and the NCI Renal Cancer Task Force, Dr. Brugarolas was the inaugural chair of the integration panel of the congressionally- directed Kidney Cancer Research Program that launched the first kidney cancer clinical trials consortium, and currently chairs the scientific advisory board of the Academy for Kidney Cancer Investigators. He serves (or served) on advisory panels and committees of NCI, ASCO, and academic programs across the country. Following a residency in internal medicine at Duke University Medical Center, he completed a fellowship in oncology at the Dana-Farber Cancer Institute, where he trained with Nobel Laureate William G. Kaelin, Jr. He holds an M.D. from the University of Navarra and a Ph.D. from MIT, where he trained with Tyler Jacks, Ph.D., former Director of the MIT Koch Institute for Integrative Cancer Research.



Corbin Eule, MD

*Assistant Professor
Genitourinary (GU) Medical Oncology
University of Colorado School of Medicine
Aurora, CO*

Corbin Eule, MD, is an Assistant Professor in the Department of Medicine, Division of Medical Oncology, at the University of Colorado Anschutz Medical Campus. He earned his BA from Grinnell College, MD from the University of Florida College of Medicine, completed residency at UT Southwestern, and completed fellowship training in medical oncology at the University of Colorado in 2023, where he was recognized as Chief Fellow.

Dr. Eule specializes in genitourinary medical oncology, with clinical expertise in bladder, kidney, prostate, testicular, and other urologic cancers. He is a clinical member of the University of Colorado Cancer Center's Developmental Therapeutics Program and serves on the Kidney Cancer Panel; his recent work includes publications on renal cell carcinoma in patients undergoing kidney transplant evaluation and neuroendocrine prostate cancer outcomes.



Catherine Fahey, MD, PhD

*Assistant Professor of Medicine
Division of Oncology,
University of North Carolina at Chapel Hill
Chapel Hill, NC*

Dr. Fahey is an Assistant Professor of Medicine in the Division of Oncology at the University of North Carolina at Chapel Hill. She is a medical oncologist and clinical researcher, with a focus on genitourinary (GU) cancers. She completed her MD and PhD in Genetics and Molecular biology at the University of North Carolina at Chapel Hill. She then completed an internal medicine residency at the Hospital of the University of Pennsylvania. She completed a fellowship in Medical Oncology at the Vanderbilt University Medical Center. She is involved in clinical trial development for GU tumors.



Christopher Gaffney, MD

*Assistant Attending Surgeon
Urologic Surgeon
Memorial Sloan Kettering Cancer Center
New York, NY*

Dr. Christopher Gaffney is a urologic surgeon and oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), where he specializes in the management of genitourinary malignancies, including prostate, bladder, kidney, and other rare urologic cancers. He sees patients at MSKCC's Basking Ridge and Monmouth locations in New Jersey and performs surgery at Memorial Hospital and the Josie Robertson Surgery Center in Manhattan. Dr. Gaffney earned his MD from Columbia University Vagelos College of Physicians and Surgeons in 2016 and completed advanced urologic oncology training at Memorial Sloan Kettering Cancer Center.

Dr. Gaffney's clinical and research interests focus primarily on prostate cancer, with an emphasis on active surveillance, transperineal prostate biopsy, and minimally invasive surgical approaches aimed at optimizing both oncologic outcomes and quality of life. He is actively involved in research efforts designed to improve treatment strategies for men with prostate cancer and collaborates closely with multidisciplinary teams in radiology, pathology, medical oncology, and radiation oncology to advance patient-centered cancer care.



Timothy Gilligan, MD

*Vice-Chair for Education
Associate Professor of Medicine
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH*

Dr. Timothy Gilligan is a medical oncologist, Vice-Chair for Education, and Associate Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio. Dr. Gilligan earned his MD from the Stanford University School of Medicine and completed his residency training in internal medicine at Brigham and Women's Hospital, followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts.

Dr. Gilligan's clinical and research interests focus primarily on genitourinary oncology, with an emphasis on testis cancer survivorship. He is an internationally recognized expert in the field and currently chairs the National Comprehensive Cancer Network (NCCN) Testis Cancer panel. He specializes in the management of urologic malignancies, including cancers of the testicles, bladder, prostate, and kidneys, with a particular interest and focus on cancer survivorship. He sees patients at the Cleveland Clinic Main Campus and has previously served as the medical director of the inpatient oncology unit and Program Director of the Hematology-Oncology Fellowship.



Hanan Goldberg, MD, MSc

*Assistant Professor
Department of Urology
SUNY Upstate Medical University
New Hartford, NY*

Dr. Goldberg received his medical degree from the Hebrew University Hadassah Medical School in Jerusalem, Israel, and his Master of Science from the University of Toronto's Institute of Medical Science in Canada.

He also served as a senior medical officer in the Israeli Defense Forces (IDF) for several years. He completed his residency at the Urology Institute of the Rabin Medical Center in Israel. He later completed a three-year clinical fellowship in Uro-Oncology with the Department of Surgical Oncology at the Princess Margaret Cancer Center in Toronto, Canada. During his fellowship, Dr. Goldberg focused on both robotic minimally invasive and open procedures. He also earned his Master of Science in Clinical Epidemiology at the University of Toronto.

Dr. Goldberg is an Assistant Professor in the Urology Department at SUNY Upstate Medical University in Syracuse, New York. He is also the Chief of the Upstate Urology service at the Mohawk Valley Healthcare System in Utica, New York. His clinical expertise includes prostate, kidney, bladder, and testicular cancers; upper tract urothelial carcinoma; adrenal disorders; and benign prostatic hyperplasia (BPH).

Dr. Hanan Goldberg has more than 120 publications in leading urology journals. He remains actively engaged in clinical and research work, promoting urologic care. He is an active member of several international urological societies and serves as a reviewer and associate editor for several major urology journals. His research focuses on prostate cancer chemoprevention, disparities in cancer screening, and financial toxicity among genitourinary cancer patients.



Amir Goldkorn, MD

*Professor of Medicine and Cancer Biology
Balakrishnan Chair for Cancer Research
Chief, Section of Laboratory Cancer Research
Division of Medical Oncology
Associate Director for Translational Research
USC Norris Comprehensive Cancer Center
Los Angeles, CA*

Amir Goldkorn, MD, is Professor of Medicine and Biochemistry & Molecular Medicine at the Keck School of Medicine of the University of Southern California, Balakrishnan Chair for Cancer Research, Chief of the Section of Laboratory Cancer Research, and Associate Director for Translational Research at USC Norris Comprehensive Cancer Center in Los Angeles. He earned his bachelor's degree magna cum laude from Harvard University and his MD from UCLA, where he also completed residency in internal medicine, followed by fellowship training in hematology/oncology at UCSF and postdoctoral research in telomerase biology in the laboratory of Nobel laureate Elizabeth Blackburn.

Dr. Goldkorn is a physician-scientist specializing in genitourinary malignancies, with research focused on liquid biopsies, circulating tumor cells, cancer cell plasticity, telomerase, and precision cancer care. He founded and directs the Liquid Biopsy Core at USC Norris, leads liquid biopsy studies in NCI-SWOG phase III genitourinary cancer trials, and chairs translational medicine for prostate cancer within SWOG; his recent work includes studies showing that early circulating tumor cell testing can predict treatment response, disease progression, and survival in metastatic prostate cancer.



Theodore Stewart Gourdin, MD

*Associate Professor
Genitourinary Medical Oncology
Hollings Cancer Center/ Medical University of South Carolina
Charleston, SC*

Dr. Theodore S. Gourdin is Associate professor and board-certified oncologist specializing in genitourinary cancer. His medical degree was awarded by the University of South Carolina School of Medicine. He completed his residency in internal medicine at Tulane University School of Medicine and his fellowship in hematology/oncology at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

Dr. Gourdin has a particular clinical interest in urothelial cancer of the bladder, with a focus on multidisciplinary, patient-centered management across the disease continuum. His work reflects a strong commitment to advancing care for patients with genitourinary malignancies through evidence-based treatment approaches, clinical expertise.




Brendan J. Guercio, MD

*Assistant Professor, Department of Medicine
Director for Genitourinary Medical Oncology
James P. Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, NY*

Dr. Brendan J. Guercio is an assistant professor and board-certified medical oncologist specializing in genitourinary malignancies. He earned his medical degree from Harvard Medical School, followed by his internship and residency training in internal medicine at Brigham and Women's Hospital. He then completed a specialized fellowship in hematology and oncology at Memorial Sloan Kettering Cancer Center, where he also served as a Visiting Investigator, alongside a prior appointment as an Instructor of Medicine at Harvard Medical School.

Dr. Guercio clinical expertise focuses on the use of cutting-edge immunotherapy, chemotherapy, and hormone therapy for urologic cancers. An active researcher, he has received Young Investigator Awards from the Bladder Cancer Advocacy Network (BCAN) and the ASCO Conquer Cancer Foundation, with ongoing research support from the NIH/NCI to develop novel therapeutic approaches through clinical trials.



Hans Hammers, MD, PhD

*Professor
Eugene P. Frenkel, M.D. Scholar in Clinical Medicine
Department of Internal Medicine
Division of Hematology and Oncology
UT Southwestern Medical Center
Dallas, TX*

Hans Hammers, MD, PhD, is a Professor in the Department of Internal Medicine and a member of the Division of Hematology and Oncology at UT Southwestern Medical Center, where he serves as the inaugural Eugene P. Frenkel, MD Scholar in Clinical Medicine. Originally from Germany, Dr. Hammers earned both his medical degree and PhD from the Medical University of Lübeck. He completed his residency in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. Prior to joining UT Southwestern in 2016, he led kidney cancer research efforts at Johns Hopkins and played a key role in the early clinical development of immune checkpoint inhibitors in renal cell carcinoma.

Dr. Hammers is an internationally recognized expert in genitourinary oncology, with a primary research focus on the development of novel immunotherapy strategies and targeted therapies for kidney cancer. His work has contributed significantly to advancing immune checkpoint blockade and combination immunotherapy approaches in renal cell carcinoma, and he has served as principal investigator on numerous industry- and investigator-sponsored clinical trials. At UT Southwestern, he is co-leader of clinical research and immunotherapy within the Kidney Cancer Research Program and the Experimental Therapeutics Program, where he continues to lead translational and clinical research efforts aimed at improving outcomes for patients with advanced kidney cancer.



Michael E. Hurwitz, MD

*Associate Professor of Medicine
Yale Cancer Center
Program Director, Hematology/Oncology Fellowship
Yale School of Medicine
New Haven, CT*

Dr. Michael Hurwitz is an Associate Professor and board-certified medical oncologist specializing in genitourinary malignancies. He earned his undergraduate degree in biochemical sciences from Harvard College, followed by a PhD from Rockefeller University and his medical degree from Cornell University Medical College. He completed his residency in medicine at The New York Presbyterian Hospital - Weill Cornell Campus, a fellowship at the Dana-Farber Cancer Institute/Brigham and Women's Hospital/Massachusetts General Hospital, and a postdoctoral fellowship at the Massachusetts Institute of Technology.

Dr. Hurwitz treats patients at the Smilow Cancer Hospital at Yale New Haven, where he has dedicated over 20 years to caring for individuals with kidney, bladder, prostate, and testicular cancers. His primary research and clinical focus centers on expanding access to innovative clinical trials, particularly evaluating immune cell-based treatments like CAR-T and tumor-infiltrating lymphocyte (TIL) therapies for solid tumor malignancies.




Rohit Jain, MBBS, MD

*Associate Professor of Medicine
Division of Genitourinary Oncology
Weill Cornell Medicine
Attending Physician
New York-Presbyterian Hospital–Weill Cornell Medical Center
New York, NY*

Dr. Rohit K. Jain, MD, MPH, is an Associate Professor of Medicine in the Division of Genitourinary Oncology at Weill Cornell Medicine and an Attending Physician at New York-Presbyterian Hospital–Weill Cornell Medical Center. He earned his medical degree (MBBS) from Topiwala National Medical College and B.Y.L. Nair Charitable Hospital in Mumbai, India. He completed his Internal Medicine residency at Johns Hopkins University/Sinai Hospital of Baltimore and went on to pursue a Hematology-Oncology fellowship at Roswell Park Cancer Institute, University at Buffalo, New York.

His research focuses on translational and clinical investigations in genitourinary malignancies—particularly bladder, kidney, prostate, and testicular cancers and the development of novel immunotherapeutic strategies. He recently co-authored the PrECOG PrE0807 Phase 1b trial evaluating neoadjuvant nivolumab (with and without lirilumab) in muscle-invasive bladder cancer in the *Annals of Oncology*.




Angela Y. Jia, MD, PhD

*Assistant Professor, Radiation Oncology
Director, GU Radiation Oncology
Co-Lead, GU Disease Program
Associate Residency Program Director
University Hospitals Cleveland Medical Center
Cleveland, OH*

Dr. Angela Jia is Assistant Professor in radiation oncology and specializing in genitourinary cancers. Her medical degree was awarded by Weill Cornell Medical College, and she earned her PhD in pathobiology and molecular medicine from Columbia University. She completed her internship in internal medicine at the University of Maryland Medical Center and her residency in radiation oncology at Johns Hopkins University School of Medicine.

Dr. Jia's clinical expertise includes stereotactic body radiation therapy (SBRT) and adaptive radiotherapy for prostate, kidney, and bladder cancers. She has a particular interest in advancing radiation oncology technology through innovative clinical trials using radiopharmaceuticals.



Prateek Khanna, MBBS

*Medical Oncologist
Dana-Farber Cancer Institute
Instructor in Medicine
Harvard Medical School
Boston, MA*

Prateek Khanna, MBBS, is a medical oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School in Boston, MA. He received his MBBS from the University of Delhi, India, completed postdoctoral research at Beth Israel Deaconess Medical Center, followed by internal medicine residency at Mount Auburn Hospital, geriatric medicine fellowship at NYU Grossman School of Medicine, and hematology/oncology fellowship at Dana-Farber.

Dr. Khanna specializes in genitourinary oncology, with research interests in kidney and prostate cancer. His work has focused on mechanisms of resistance to VEGFR tyrosine kinase inhibitors in clear cell renal cell carcinoma, and he received a 2023 Kidney Cancer Association Translocation RCC Focus Award for research on therapeutic targeting of cell-surface antigens in translocation renal cell carcinoma.



Jennifer King, MD

*Assistant Professor of Clinical Medicine
Associate Fellowship Program Director, Division of Hematology/Oncology
Indiana University Simon Comprehensive Cancer Center
Indianapolis, IN*

Dr. Jennifer M. King is an Assistant Professor and board-certified medical oncologist specializing in genitourinary malignancies. She earned her undergraduate degree from Purdue University and her medical degree from the Indiana University School of Medicine, where she also completed her internal medicine residency, served as chief resident, and completed her specialized hematology/oncology fellowship training.

Dr. King's research interests focus on clinical investigation in genitourinary oncology, with a particular emphasis on renal cell carcinoma and predictive biomarkers of treatment response. Her work aims to better understand which patients are most likely to benefit from specific therapies and to support more personalized treatment selection in advanced kidney cancer. She is also involved in protocol development and phase 2 clinical trials designed to expand therapeutic options for patients with urologic malignancies.



Eric Jonasch, MD

*Professor
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX*

Dr. Jonasch is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Center at the University of Texas M. D. Anderson Cancer Center in Houston, Texas. He is director of the VHL Clinical Center at the MD Anderson Cancer Center, co-Director of the MD Anderson Kidney Cancer Research Program, and performs clinical, translational and basic research in kidney carcinoma and VHL disease.

Dr. Jonasch has authored over 190 articles published in peer-reviewed journals and is editor of the textbook: Kidney Cancer, Principles and Practice. Dr. Jonasch has a long history of service in the kidney cancer community. He serves as Vice-Chair of the NCCN Kidney Cancer Guideline Panel, is a member of the U.S. NCI Renal Task Force and is a Board member of the VHL Alliance.



Janet Kukreja, MD, MPH, FACS

*Director of Urologic Oncology
Associate Professor, Surgery-Urology
University of Colorado
Aurora, CO*

Janet Kukreja, MD, MPH, is Associate Professor of Urology at the University of Colorado School of Medicine and Director of Urologic Oncology at the University of Colorado Cancer Center and UCHealth University of Colorado Hospital. She earned her medical degree through the combined BA/MD program at the University of Missouri–Kansas City School of Medicine and completed her urology residency at the University of Rochester, where she also obtained a Master of Public Health degree. Dr. Kukreja subsequently completed a fellowship in urologic oncology at The University of Texas MD Anderson Cancer Center, with advanced training in minimally invasive and robotic surgery for urologic cancers.

Dr. Kukreja's clinical and research interests focus on bladder cancer, robotic radical cystectomy, urinary diversion, and perioperative care optimization for patients with urologic malignancies. She is recognized as one of the leading robotic bladder cancer surgeons in North America and performs a high volume of robotic cystectomies annually, including intracorporeal urinary diversions and neobladder reconstruction. Her research has contributed to advancements in surgical outcomes, enhanced recovery pathways, and cost-effectiveness analyses in bladder cancer surgery, and she has authored numerous peer-reviewed publications in urologic oncology.



Timothy M. Kuzel, MD, FACP

Clinical Professor of Medicine, Feinberg School of Medicine, Northwestern University
Associate Director of Clinical Research Network, Robert H. Lurie Comprehensive Cancer Center
Distinguished Physician, St George Foundation
Oncology Service Line Director, NM South Region
Chicago, IL

Dr. Kuzel received his medical degree from the University of Michigan in 1984. He completed an internship and residency in internal medicine, as well as a fellowship in hematology/oncology at Northwestern University. He is board certified in internal medicine and oncology, and is board eligible in hematology, and is a diplomate of the National Board of Medical Examiners.

Dr. Kuzel was on the faculty of Northwestern University from 1990 thru 2016 achieving status of full Professor of Medicine with a joint appointment in Dermatology. While there he directed the GU and Cutaneous Oncology Programs for over 25 years. He has had a long interest in developing novel immunotherapy approaches to the diseases in the program and was the Director of the Driskill Immunotherapy Research Program at Northwestern University, a program focused on developing novel laboratory and clinical approaches for immunology-based treatments of prostate cancer. Dr Kuzel was the Chief of the Division of Hematology/Oncology/Cell therapy at Rush University Medical School from 2016 thru 2023. He is now a Clinical Professor of Medicine at the Feinberg School of Medicine of Northwestern University, oncology service line director of the south region of Northwestern Medicine, and an Associate Director for the Northwestern Medicine network in cancer clinical research in the Robert H. Lurie Comprehensive cancer center of Northwestern University.

Dr. Kuzel has received an American Cancer Society Clinical Oncology Career Development Award early in his career, received teaching awards at Northwestern University and has been frequently listed as one of Chicago's and US News and World Reports Best Doctors. He has authored or co-authored over 350 journal articles, editorials, and book chapters and has edited several textbooks.




Andrew T. Lenis, MD

*Assistant Professor of Urology
Department of Urology
Columbia University Irving Medical Center
New York, NY*

Dr. Andrew T. Lenis, MD, MS, is an Assistant Professor of Urology at Columbia University Irving Medical Center in New York, New York, where he specializes in urologic oncology. His clinical expertise includes the management of bladder, kidney, prostate, testicular, and penile cancers. Dr. Lenis earned his dual MD/MS degree with Honors Distinction in Research from Case Western Reserve University School of Medicine in Cleveland, Ohio. He subsequently completed his surgical internship and urology residency at the University of California, Los Angeles (UCLA), followed by a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Lenis is a surgeon-scientist whose research focuses on urothelial carcinoma and the molecular biology of bladder cancer. He collaborates extensively in translational research involving bladder tumor organoids and precision oncology approaches. His research has been supported by the American Urological Association, the American Cancer Society, and the American Society of Clinical Oncology. Dr. Lenis has authored numerous influential publications in leading journals including JAMA, European Urology, Journal of Urology, and Journal of Clinical Oncology Precision Oncology. His work has contributed significantly to advancing the understanding of molecular classification, immunotherapy, and genomic heterogeneity in urothelial malignancies.



Murilo De Almeida Luz, MD

*Assistant Professor of Urology
Icahn School of Medicine at Mount Sinai
New York, NY*

Dr. Murilo De Almeida Luz is a urologic oncologist and Assistant Professor of Urology at the Icahn School of Medicine at Mount Sinai in New York, New York. Dr. Luz earned his medical degree from the Universidade Federal do Paraná. He subsequently completed residency training in general surgery at the Universidade de São Paulo and in surgical oncology, followed by an advanced fellowship in urologic oncology and robotic surgery at McGill University Hospital.

He specializes in the surgical and medical management of genitourinary malignancies, with a dedicated clinical focus on prostate cancer, familial prostate cancer, and complex urologic conditions. Dr. Luz's clinical and research interests focus primarily on advanced prostate cancer, utilizing minimally invasive and robotic surgical techniques to optimize oncological and functional outcomes for his patients. He is actively involved in clinical trial investigations and real-world evidence analyses evaluating novel therapeutic combinations and androgen receptor pathway inhibitors for metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer. As an accomplished researcher and speaker, Dr. Luz frequently collaborates with international multidisciplinary panels and contributes peer-reviewed data to advance precision urologic oncology and patient-centered care.



Hannah Dzimitrowicz McManus, MD

*Assistant Professor of Medicine
Division of Medical Oncology
Department of Medicine
Duke University Medical Center*

Hannah Dzimitrowicz McManus, MD, is an Assistant Professor of Medicine in the Division of Medical Oncology at Duke University School of Medicine and a member of the Duke Cancer Institute. She specializes in the treatment of genitourinary malignancies, including bladder, kidney, prostate, and testicular cancers. Dr. McManus earned her medical degree from Georgetown University School of Medicine and completed her residency in internal medicine at Duke University Medical Center, where she also completed a fellowship in hematology and medical oncology. Her clinical practice emphasizes multidisciplinary and patient-centered care for individuals with advanced genitourinary cancers.

Dr. McManus's research interests focus on the development of novel therapeutics and immunotherapy approaches for genitourinary malignancies, with a particular emphasis on clinical trials in bladder and kidney cancer. She is actively involved in translational and early-phase clinical research aimed at improving outcomes and expanding treatment options for patients with advanced disease. In addition to her research and clinical work, Dr. McManus is committed to medical education and mentorship within the Duke oncology community and has contributed to multiple peer-reviewed publications and national oncology presentations in the field of genitourinary oncology.



Mamta Parikh, MD, MS

*Associate Professor,
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA*

Mamta Parikh, MD, MS, is an Associate Professor in the Division of Hematology and Oncology at UC Davis Comprehensive Cancer Center in Sacramento, California. She earned her BS in Chemistry from Boston University, MS in Organic Chemistry from UC Irvine, and MD from UC Davis School of Medicine, followed by internal medicine residency and hematology/oncology fellowship training at UC Davis Medical Center.

Dr. Parikh is a genitourinary medical oncologist specializing in bladder, kidney, prostate, and testicular cancers. Her research focuses on improving outcomes in bladder, kidney, and prostate cancer through clinical trials of novel agents, cancer outcomes research in California, and strategies to enhance immunotherapy efficacy in bladder cancer. Her recent scholarly work includes publications in prostate cancer, bladder cancer, clinical trials, and physician-scientist training.



Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and Urology

Chief, Genitourinary Oncology

Director of Genitourinary Oncology, Co Director Signal Transduction Program

Yale School of Medicine

New Haven, CT

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”

At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.

Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also the co-director of the Cancer Signaling Networks Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.

One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”

Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.



Dana E. Rathkopf, MD

*Member, Memorial Hospital
Memorial Sloan Kettering Cancer Center
Clinical Professor of Medicine
Weill Cornell Medical College
New York, NY*

Dr. Dana Rathkopf is a medical oncologist at Memorial Sloan Kettering Cancer Center (MSK) and a Clinical Professor of Medicine at Weill Cornell Medical College. She has played a leading role in the development and approval of clinical trials targeting the androgen receptor, both as monotherapy and in combination with other agents, with the goal of overcoming resistance and improving outcomes for patients with advanced prostate cancer. Nationally, she serves as the site principal investigator at MSK for the Prostate Cancer Clinical Trials Consortium, an initiative aimed at expanding patient access to clinical trials. In addition to her scientific leadership, Dr. Rathkopf holds key institutional roles as Deputy Associate Director of Clinical Research and Chair of the Research Council at MSK, where she oversees clinical trial review and helps guide institutional research priorities.



Rosa Nadal Rios, MD, PhD

*GU Medical Oncology
Associate Professor
University of Washington School of Medicine
Fred Hutchinson Cancer Center.
Seattle, WA*

Dr. Rosa Nadal Rios is an Associate Professor and board-certified medical oncologist at University of Washington where she is specialized in genitourinary tumors. She earned her medical degree and PhD from the Universitat Autònoma de Barcelona, followed by specialized fellowship training in genitourinary oncology at Johns Hopkins University and hematology/oncology at the National Institutes of Health (NIH).

Her clinical and research interests focus on improving outcomes for patients with genitourinary tumors through novel targeted therapies, immunotherapy-based approaches, and cellular therapy for solid tumors. She has a particular interest in bladder cancer and in bringing engineered immune-cell approaches to urologic malignancies. Notably, Dr. Nadal Rios developed the first clinical trial evaluating engineered T cells targeting human endogenous retrovirus E for kidney cancer, reflecting her broader commitment to translating advances in tumor immunology into new treatment strategies for patients with kidney and bladder cancers.



Charles James Ryan, MD

Member

Attending Physician

Memorial Sloan Kettering Cancer Center

New York, NY

Dr. Charles J. Ryan is a genitourinary medical oncologist with a specialization in treating prostate cancer, particularly advanced prostate cancer that has metastasized to other parts of the body. He sees patients at the Sidney Kimmel Center for Prostate and Urologic Cancers in New York City and Memorial Sloan Kettering Monmouth in New Jersey. He takes pride in getting to know his patients and their families, making sure they understand their diagnosis, and explaining the various treatment options available, such as hormonal therapies, chemotherapy, targeted therapy, and radioligand therapy, which involves directing radiation to targeted cancer cells.

As a dedicated clinician, Dr. Ryan values building long-term relationships with his patients. In addition to his clinical work, he is deeply involved in research and has led numerous clinical trials and research teams focused on prostate cancer biology, treatment, and supportive care. His research has received funding from the National Institutes of Health, the Department of Defense Prostate Cancer Research Program, and the Prostate Cancer Foundation. He has authored more than 200 articles and book chapters in leading medical journals and wrote *The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In*. Previously, he served as Chair of the National Cancer Institute's GU Steering Committee's Prostate Cancer Task Force and as Chief Executive Officer of the Prostate Cancer Foundation. Currently, Dr. Ryan is the Medical Director of the Prostate Cancer Clinical Trials Consortium and a member of the Advanced Prostate Cancer Consensus Conference.



Oliver Sartor, MD

*Director, Transformational Prostate Cancer Research Center
LCMC Health
Metairie, LA*

Dr. Sartor received his MD from Tulane University School of Medicine with honors in 1982. After an internship at the University of Pennsylvania, he trained in internal medicine at Tulane Medical School. After completing a fellowship at the National Cancer Institute (NCI) in Bethesda, Maryland in 1989, he served until 1993 as a senior investigator at the NCI and began focusing on novel therapeutics for advanced prostate cancer patients. Dr. Sartor returned to Louisiana in 1993 to serve as an Associate Professor at the LSU Medical School in Shreveport and then moved to the LSU Health Sciences Center in New Orleans in 1998 as the Patricia Powers Strong Professor of Oncology, the Stanley S. Scott Cancer Center Director, and the Hematology/Oncology Section Chief. He was the Co-Director of the Louisiana Cancer Research Consortium, starting at its legislative inception in 2002. In March 2006, he left LSU to join the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and the Harvard Medical School. In January 2008, Dr. Sartor joined Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology.

An internationally recognized expert in prostate cancer, Dr. Sartor's interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.

Having published over 500 scholarly articles and having served as the past Chairman of the Department of Defense Prostate Integration Panel, Dr. Sartor, in addition to being the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology, is the Medical Oncology Chair of the GU Committee of the NRG, the Assistant Dean for Oncology at Tulane University School of Medicine, the Medical Director of the Tulane Cancer Center, and the Editor-in-Chief of the peer-reviewed journal, Clinical Genitourinary Cancer. In addition, he is currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).



David B. Solit, MD

*Geoffrey Beene Chair in Cancer Research
Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Chief, Molecular Medicine Service, Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center
New York, NY*

David B. Solit, MD, is a physician-scientist and internationally recognized leader in precision oncology at Memorial Sloan Kettering Cancer Center (MSKCC). He serves as the Geoffrey Beene Chair for Cancer Biology and Chief of the Division of Solid Tumor Oncology within the Department of Medicine at MSKCC, and is also a Professor of Medicine at Weill Cornell Medical College. Dr. Solit earned his medical degree from the University of Pennsylvania School of Medicine and completed his residency in internal medicine at Massachusetts General Hospital, followed by a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Throughout his career, he has played a pivotal role in integrating genomic profiling into cancer care and advancing molecularly targeted therapies.

Dr. Solit's research focuses on cancer genomics, mechanisms of resistance to targeted therapies, and the development of precision medicine strategies across solid tumors. He was instrumental in the development and implementation of MSK-IMPACT, a widely adopted next-generation sequencing platform used for comprehensive tumor profiling, and has contributed to landmark discoveries involving BRAF, FGFR, and other actionable oncogenic drivers. His translational research has significantly influenced biomarker-driven clinical trial design and personalized cancer therapy, and he has authored numerous high-impact publications in leading journals including Nature, Cancer Discovery, and The New England Journal of Medicine.



Srikala Sridhar, MD, MSc, FRCPC

*Staff Medical Oncologist
GU Site Group Lead
Princess Margaret Cancer Center
Professor, Medical Oncology,
University of Toronto,
Toronto, Ontario, Canada*

Dr. Srikala Sridhar holds the position of Professor in the Department of Medicine at the University of Toronto, and is a Genitourinary Medical Oncologist and Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada, Vice Chair of the Medical Advisory Board of Bladder Cancer Canada as well as the K. Y. Ho chair in Prostate Cancer Research. Additionally, she contributes her expertise as a member of the Canadian Clinical Trials Group - Genitourinary Disease Site Executive Committee, and the US National Cancer Institute Bladder Cancer Task Force. Her primary research focus lies in new drug development and Phase II clinical trials. She has significantly impacted the field of genitourinary oncology through her involvement as a principal or co-investigator on numerous industry and investigator initiated clinical trials, including several practice changing trials. With a specialization in advanced urothelial cancers, she is recognized internationally for her expertise. Her recent contributions to the field can be found in the New England Journal of Medicine, JAMA Oncology, and European Urology.

In recognition of her dedication and excellence in teaching and mentorship, Dr. Sridhar was honored with the University of Toronto, Department of Medicine, Postgraduate Medicine Teaching Award in 2011 and the Robert Hyland Mentorship Award in 2020.



Walter Stadler, MD, FACP, FASCO

*Chief Clinical Officer,
City of Hope Cancer Center Chicago
Professor,
Department of Medical Oncology & Therapeutics Research
Chicago, IL*

As chief clinical officer at City of Hope® Cancer Center Chicago, Walter Stadler, M.D., F.A.C.P., oversees physician recruitment and clinical care for patients receiving treatment at our locations across Illinois, Southeastern Wisconsin and the surrounding areas. In this senior leadership position, Dr. Stadler ensures that every person receives the compassionate, high-quality care they deserve, as well as access to breakthrough treatments developed across City of Hope's national network.

A medical oncologist and genitourinary cancer specialist with more than 30 years' experience across clinical, academic and research settings, Dr. Stadler is committed to expanding access to innovative cancer care. Before joining City of Hope, he held multiple clinical and leadership positions at the University of Chicago School of Medicine, including Deputy Director of the University of Chicago Comprehensive Cancer Center and Associate Dean for Clinical Research.

After earning his medical degree at Yale University School of Medicine in New Haven, Connecticut, Dr. Stadler completed a residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago, followed by a fellowship in hematology and oncology at the University of Chicago. He is board-certified in medical oncology and a member of multiple professional organizations, including the American Society of Clinical Oncology, the American Association of Cancer Research and the Society for Clinical and Translational Science.


A physician-scholar, Dr. Stadler has more than 400 peer-reviewed journal articles to his name. His research interests include developing new treatment options for genitourinary cancers and bringing more access to clinical trials to underserved communities. In addition to his leadership role, Dr. Stadler continues to serve patients diagnosed with prostate, kidney, testicular or bladder cancer.



Chad Tang, MD

*Associate Professor
Department of Genitourinary Radiation Oncology
Division of Radiation Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX*

Chad Tang is a radiation oncologist at MD Anderson Cancer Center and associate professor in the department of genitourinary radiation oncology. He holds joint appointments in the department of investigational cancer therapeutics and translational molecular pathology. He received his MD from Stanford University and completed residency at MD Anderson Cancer Center. His research and clinical practice focus on the treatment of advanced prostate and renal cell carcinomas with an emphasis on oligometastatic and oligoprogressive patients. He has completed and continues to run several investigator-initiated clinical trials investigating these disease states with a translational emphasis on immune and circulating tumor bioanalytes.




Hong Truong, MD, MS

*Urologic Surgeon
Memorial Sloan Kettering Cancer Center
New York, NY*

Dr. Hong Truong, MD, MS, is a board-certified urologic surgeon at Memorial Sloan Kettering Cancer Center (MSK), where she specializes in the surgical management of prostate cancer across all stages of disease. She practices at the Sidney Kimmel Center for Prostate and Urologic Cancers in New York City and works within a multidisciplinary team focused on delivering personalized cancer care. Dr. Truong earned her medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has developed expertise in urologic oncology, minimally invasive surgical approaches, and precision-based cancer treatment strategies.

Dr. Truong's clinical and research interests center on improving the diagnosis and treatment of genitourinary malignancies, with a particular emphasis on cancer genetics and precision oncology. Her work explores how inherited and tumor-specific genetic mutations influence cancer development, progression, and therapeutic response, with the goal of advancing individualized treatment approaches for patients with prostate cancer. At MSK, she is actively involved in collaborative translational research efforts aimed at integrating genomic profiling and innovative treatment strategies into clinical practice to improve patient outcomes and quality of life.



Ulka Vaishampayan, MD, FASCO

*Beverly Mitchell Research Professor of Oncology
Co-Leader of Translational Clinical Research Program
University of Michigan/Rogel Cancer Center
Ann Arbor MI*

Ulka Vaishampayan, MD, is Professor of Internal Medicine and Director of the Phase I Program at the University of Michigan Rogel Cancer Center, where she also co-leads the Translational and Clinical Research Program. She earned her medical degree from Byramjee Jeejeebhoy Medical College in Pune, India, and completed residency in internal medicine and fellowship in hematology/oncology at Wayne State University.

Dr. Vaishampayan specializes in genitourinary malignancies, including kidney, bladder, and prostate cancers, with research focused on translational drug development, early-phase clinical trials, and biomarker-driven approaches. Her recent leadership includes serving as Chair of the SWOG Advanced Renal Committee, membership on the NCI Renal Task Force, and principal investigator for a Department of Defense Kidney Cancer Research Consortium grant.



Sara E. Wobker, MD, MPH

*Associate Professor with Tenure
Department of Pathology and Laboratory Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC*

Dr. Sara Wobker is an Associate Professor of Pathology and Laboratory Medicine and Urology at the University of North Carolina at Chapel Hill, where she also serves as the Director of Anatomic Pathology and Director of Genitourinary Pathology. She completed her Anatomic and Clinical Pathology training and cytopathology fellowship at UNC, followed by a fellowship in Urologic Surgical Pathology at Johns Hopkins. Her research spans all genitourinary malignancies, with a focus on urothelial carcinoma and its subtypes, along with understanding the histopathology following neoadjuvant therapy in bladder and kidney tumors.



JIWON LEE
j.lee@davaonc.com

GREGORY PYNES
gpynes@davaonc.com

KARTIK VITTALA
Kvittala@davaonc.com

DAVA ONCOLOGY
5930 Royal Ln, Ste E, Dallas , TX 75230
www.davaonc.com